156 related articles for article (PubMed ID: 27133418)
1. Potential of tocotrienols in the prevention and therapy of Alzheimer's disease.
Xia W; Mo H
J Nutr Biochem; 2016 May; 31():1-9. PubMed ID: 27133418
[TBL] [Abstract][Full Text] [Related]
2. Tocotrienols potentiate lovastatin-mediated growth suppression in vitro and in vivo.
McAnally JA; Gupta J; Sodhani S; Bravo L; Mo H
Exp Biol Med (Maywood); 2007 Apr; 232(4):523-31. PubMed ID: 17392488
[TBL] [Abstract][Full Text] [Related]
3. Mevalonate-suppressive dietary isoprenoids for bone health.
Mo H; Yeganehjoo H; Shah A; Mo WK; Soelaiman IN; Shen CL
J Nutr Biochem; 2012 Dec; 23(12):1543-51. PubMed ID: 22981371
[TBL] [Abstract][Full Text] [Related]
4. Regulation of the brain isoprenoids farnesyl- and geranylgeranylpyrophosphate is altered in male Alzheimer patients.
Eckert GP; Hooff GP; Strandjord DM; Igbavboa U; Volmer DA; Müller WE; Wood WG
Neurobiol Dis; 2009 Aug; 35(2):251-7. PubMed ID: 19464372
[TBL] [Abstract][Full Text] [Related]
5. Isoprenoids, small GTPases and Alzheimer's disease.
Hooff GP; Wood WG; Müller WE; Eckert GP
Biochim Biophys Acta; 2010 Aug; 1801(8):896-905. PubMed ID: 20382260
[TBL] [Abstract][Full Text] [Related]
6. The Potential of Isoprenoids in Adjuvant Cancer Therapy to Reduce Adverse Effects of Statins.
Mo H; Jeter R; Bachmann A; Yount ST; Shen CL; Yeganehjoo H
Front Pharmacol; 2018; 9():1515. PubMed ID: 30662405
[TBL] [Abstract][Full Text] [Related]
7. Effects of farnesyl pyrophosphate accumulation on calvarial osteoblast differentiation.
Weivoda MM; Hohl RJ
Endocrinology; 2011 Aug; 152(8):3113-22. PubMed ID: 21586555
[TBL] [Abstract][Full Text] [Related]
8. Modulation of cholesterol, farnesylpyrophosphate, and geranylgeranylpyrophosphate in neuroblastoma SH-SY5Y-APP695 cells: impact on amyloid beta-protein production.
Hooff GP; Peters I; Wood WG; Müller WE; Eckert GP
Mol Neurobiol; 2010 Jun; 41(2-3):341-50. PubMed ID: 20405344
[TBL] [Abstract][Full Text] [Related]
9. Brain isoprenoids farnesyl pyrophosphate and geranylgeranyl pyrophosphate are increased in aged mice.
Hooff GP; Wood WG; Kim JH; Igbavboa U; Ong WY; Muller WE; Eckert GP
Mol Neurobiol; 2012 Aug; 46(1):179-85. PubMed ID: 22692983
[TBL] [Abstract][Full Text] [Related]
10. Geranylgeranyl pyrophosphate is a potent regulator of HRD-dependent 3-Hydroxy-3-methylglutaryl-CoA reductase degradation in yeast.
Garza RM; Tran PN; Hampton RY
J Biol Chem; 2009 Dec; 284(51):35368-80. PubMed ID: 19776008
[TBL] [Abstract][Full Text] [Related]
11. Risk of Late-Onset Alzheimer's Disease by Plasma Cholesterol: Rational In Silico Drug Investigation of Pyrrole-Based HMG-CoA Reductase Inhibitors.
Shahbazi S; Kaur J; Kuanar A; Kar D; Singh S; Sobti RC
Assay Drug Dev Technol; 2017; 15(7):342-351. PubMed ID: 29077483
[TBL] [Abstract][Full Text] [Related]
12. Tocotrienol Affects Oxidative Stress, Cholesterol Homeostasis and the Amyloidogenic Pathway in Neuroblastoma Cells: Consequences for Alzheimer's Disease.
Grimm MO; Regner L; Mett J; Stahlmann CP; Schorr P; Nelke C; Streidenberger O; Stoetzel H; Winkler J; Zaidan SR; Thiel A; Endres K; Grimm HS; Volmer DA; Hartmann T
Int J Mol Sci; 2016 Oct; 17(11):. PubMed ID: 27801864
[TBL] [Abstract][Full Text] [Related]
13. Post-transcriptional regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase by mevalonate.
Straka MS; Panini SR
Arch Biochem Biophys; 1995 Feb; 317(1):235-43. PubMed ID: 7872789
[TBL] [Abstract][Full Text] [Related]
14. Statins: the role in the treatment and prevention of Alzheimer's neurodegeneration.
Pac-Soo C; Lloyd DG; Vizcaychipi MP; Ma D
J Alzheimers Dis; 2011; 27(1):1-10. PubMed ID: 21734347
[TBL] [Abstract][Full Text] [Related]
15. The analytical determination of isoprenoid intermediates from the mevalonate pathway.
Nürenberg G; Volmer DA
Anal Bioanal Chem; 2012 Jan; 402(2):671-85. PubMed ID: 21789486
[TBL] [Abstract][Full Text] [Related]
16. Hepatic farnesyl diphosphate synthase expression is suppressed by polyunsaturated fatty acids.
Le Jossic-Corcos C; Gonthier C; Zaghini I; Logette E; Shechter I; Bournot P
Biochem J; 2005 Feb; 385(Pt 3):787-94. PubMed ID: 15473864
[TBL] [Abstract][Full Text] [Related]
17. Chemoprevention of tocotrienols: the mechanism of antiproliferative effects.
Wada S
Forum Nutr; 2009; 61():204-216. PubMed ID: 19367124
[TBL] [Abstract][Full Text] [Related]
18. The mevalonate suppressor δ-tocotrienol increases AMPA receptor-mediated neurotransmission.
Wei W; Yount ST; Allen ZD; Bechdol KF; Xia W; Mo H; Mabb AM
Biochem Biophys Res Commun; 2023 Jan; 638():112-119. PubMed ID: 36446153
[TBL] [Abstract][Full Text] [Related]
19. Suppression of mevalonate pathway activities by dietary isoprenoids: protective roles in cancer and cardiovascular disease.
Elson CE
J Nutr; 1995 Jun; 125(6 Suppl):1666S-1672S. PubMed ID: 7782923
[TBL] [Abstract][Full Text] [Related]
20. Anti-cancer therapy: targeting the mevalonate pathway.
Swanson KM; Hohl RJ
Curr Cancer Drug Targets; 2006 Feb; 6(1):15-37. PubMed ID: 16475974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
